Congress Asset Management Co. MA Has $26.65 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Congress Asset Management Co. MA increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 920,808 shares of the specialty pharmaceutical company’s stock after buying an additional 3,644 shares during the period. Congress Asset Management Co. MA’s holdings in Supernus Pharmaceuticals were worth $26,648,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $1,049,000. Schroder Investment Management Group purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth $15,685,000. Vanguard Group Inc. boosted its position in Supernus Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company’s stock worth $167,410,000 after purchasing an additional 28,711 shares during the last quarter. Axiom Investors LLC DE boosted its position in Supernus Pharmaceuticals by 255.9% in the fourth quarter. Axiom Investors LLC DE now owns 48,455 shares of the specialty pharmaceutical company’s stock worth $1,402,000 after purchasing an additional 34,840 shares during the last quarter. Finally, Trust Point Inc. purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth $325,000.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 14,491 shares of the firm’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $35.31, for a total value of $511,677.21. Following the completion of the transaction, the vice president now owns 8,570 shares in the company, valued at approximately $302,606.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, VP Padmanabh P. Bhatt sold 12,364 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the sale, the vice president now owns 8,570 shares in the company, valued at $302,606.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 14,491 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the sale, the vice president now owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The disclosure for this sale can be found here. Company insiders own 8.76% of the company’s stock.

Supernus Pharmaceuticals Stock Down 2.1 %

Shares of Supernus Pharmaceuticals stock traded down $0.57 during trading on Friday, hitting $25.99. 413,875 shares of the stock traded hands, compared to its average volume of 575,032. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -89.62 and a beta of 0.93. The firm’s fifty day moving average is $28.92 and its 200-day moving average is $29.31. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $35.44.

Analyst Ratings Changes

Separately, Piper Sandler dropped their price target on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 28th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.